Skip to main
SXTP
SXTP logo

SXTP Stock Forecast & Price Target

SXTP Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

60 Degrees Pharmaceuticals Inc. has demonstrated significant growth in net product revenues, which surged by 140% to $607.6k in FY24, alongside a sequential revenue increase of 20% and a year-over-year growth of 145%. The consistent sales growth of ARAKODA, paired with tafenoquine’s favorable safety profile and potential for expanded clinical applications, underscores a promising trajectory for the company’s product pipeline. Furthermore, the rise in babesiosis cases, reported by the CDC, highlights an increasing market demand that could further enhance ARAKODA's commercialization opportunities.

Bears say

60 Degrees Pharmaceuticals Inc faces a negative outlook primarily due to a significant revenue decline, with product revenues dropping to $100,000, caused by supply constraints despite some offset from Australian research grant revenue. The company also suffers from low visibility on the ramp-up of revenue and potential regulatory approvals, contributing to pessimism regarding its financial trajectory. Additionally, concerns regarding cash burn and possible dilution from future financing exacerbate the risks associated with investing in the company.

SXTP has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 60 Degrees Pharmaceuticals Inc (SXTP) Forecast

Analysts have given SXTP a Strong Buy based on their latest research and market trends.

According to 2 analysts, SXTP has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

60 Degrees Pharmaceuticals Inc (SXTP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.